The AIDS Reader.
Acute Renal Failure in Patients With AIDS on Tenofovir While Receiving Prolonged Vancomycin Course for Osteomyelitis
By George Psevdos Jr, MD; Efrain Gonzalez, MD; Victoria Sharp, MD |
May 28, 2009
Dr Psevdos and Dr Gonzalez are clinical instructors of medicine and Dr Sharp is assistant professor of medicine at Columbia University College of Physicians and Surgeons, Center for Comprehensive Care, St Luke’s Roosevelt Hospital, New York.
Our report is weakened by our failure to obtain a kidney biopsy in either patient; tissue examination might have clarified the chain of events. Further, without a systematic method of reporting transient drug toxicities, we are unable to estimate how frequently acute renal failure may result from coadministration of these drugs. Nevertheless, we feel that clinicians should be vigilant about monitoring renal function closely in patients receiving tenofovir who require prolonged vancomycin(Drug information on vancomycin) therapy and should be proactive in carefully adjusting the doses of both drugs at the slightest indication of renal compromise to avoid the possibility of serious renal failure.
Acknowledgment: We would like to thank Dr Abigail Zuger for reviewing our manuscript.
No potential conflict of interest relevant to this article was reported by the authors.
1. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40:1331-1333.
2. Gaspar G, Monereo A, García-Reyne A, de Guzmán M. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS. 2004;18:351-352.
3. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients; three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070-1073.
4. Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42:283-290.
5. Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001;20:641-648.
6. Krogstad DJ, Moellering RC Jr, Greenblatt DJ. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol. 1980;20:197-201.
7. Servais H, Mingeot-Leclercq MP, Tulkerns PM. Antibiotic induced nephrotoxicity. In: Lash LH, Tarloff JB, eds. Toxicology of the Kidney. 3rd ed. Boca Raton, FL: CRC Press; 2004.
8. Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother. 1983;23:138-141.
9. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990;25:679-687.
10. Sokol PP. Mechanism of vancomycin transport in the kidney: studies in rabbit renal brush border and basolateral membrane vesicles. J Pharmacol Exp Ther. 1991;259:1283-1287.
11. Dieterich C, Puey C, Lyn A, et al. Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates. Toxicol Sci. 2009;107:258-269.